OncoAlert

The OncoAlert

Join our Urology colleagues, Dr. Melao and Dr. Spiess, as they discuss upper tract urothelial carcinoma—from risk stratification to management strategies in both low-risk and high-risk, high-grade settings. They'll also explore long-term renal function outcomes, a topic on which Dr. Spiess has recently published.

Dr. Evandro de Azambuja discusses the final analysis of the APHINITY Breast Cancer trial just presented at ESMO Breast 2025.

Discussing:Association between risk-reducing surgeries and survival in young BRCA carriers with #BreastCancer DESTINY-Breast11 Update from IndustryPALMIRA in Breast #Cancer (Palbo rechallenge)PEACE V STORM in #Prostate CancerMAGNITUDE :Niraparib and Abiraterone Acetate plus Prednisone in Met CR Prostate CancerOS EGFR-mutant AdvancedNon-Small Cell #LungCancer Treated with 1L Osimertinib Cemiplimab monotherapy as 1L treatment of patients with brain metastases from advanced #NSCLC with  PDL1 ≥50%Beyond fluorodeoxyglucose: Molecular imaging of cancer in precision medicine and more

This international retrospective cohort study evaluated the safety of assisted reproductive technology (ART) in BRCA1/2 carriers who conceived after a breast cancer diagnosis at age 40 or younger. Among 543 women, 107 conceived using ART and 436 conceived spontaneously. ART methods included oocyte/embryo cryopreservation, in vitro fertilization, ovulation induction, and oocyte donation. Patients who used ART were generally older, had more hormone receptor-positive tumors, and a longer interval from diagnosis to conception. After a median follow-up of 5.2 years post-conception, ART use was not associated with an increased risk of disease-free survival events, suggesting that ART is a safe option for pregnancy after breast cancer in this population.

Join Dr. Jemal & Dr Morgan as they discuss this report, a collaboration among major U.S. cancer surveillance organizations, presents the latest national data on cancer incidence and mortality. Using data from cancer registries and national vital statistics, the analysis shows that while overall cancer death rates have steadily declined over the past 20 years — including during the COVID-19 pandemic — the annual rate of decline has recently slowed. Cancer incidence rates remained stable among males and rose slightly among females over time, with a temporary dip across all groups in 2020 likely due to pandemic-related disruptions in healthcare access. However, incidence rates rebounded to prepandemic levels by 2021, suggesting a limited long-term impact of COVID-19 on cancer detection trends.https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.35833

Cohort study evaluated the use of ablative radiation therapy (A-RT) as a noninvasive alternative to surgery in 25 patients with technically resectable pancreatic ductal adenocarcinoma (PDAC) who were ineligible for surgery due to comorbidities. Conducted at Memorial Sloan Kettering Cancer Center between 2016 and 2022, the study found that A-RT, delivered with high precision and dose intensity, provided promising local control and overall survival, with a 2-year OS rate of 43.7% and manageable toxicity. Despite advanced age, poor performance status, and limited chemotherapy use in the cohort, outcomes suggest A-RT may be a viable local therapy for select patients with resectable PDAC, warranting further prospective investigation.Link to Arcticlehttps://jamanetwork.com/journals/jamaoncology/article-abstract/2832566

The OncoAlertWeekly Round Up   Covering the TOP of the week April 18-24, 2025  REGISTER at http://OncoAlert360.com OR https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration   Discussing:UPDATE on DESTINY-Breast09https://astrazeneca.com/media-centre/press-releases/2025/enhertu-combination-improved-pfs-in-1l-her-positive-mbc.htmlUPDATE on ASCENT 04https://gilead.com/news/news-details/2025/trodelvy-plus-keytruda-demonstrates-a-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-previously-untreated-pd-l1-metastatic-tripAnnual Report to the Nationon the Status of Cancer, featuring state-level statistics after the onset of the COVID-19 pandemichttps://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.35833Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer https://lungcancerjournal.info/article/S0169-5002(25)00443-X/fulltextTargeting Lung Cancer with Precision: The ADC Therapeutic Revolutionhttps://link.springer.com/article/10.1007/s11912-025-01655-5Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patientshttps://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djaf048/8101485?login=falseEuropean screening platform for EORTC clinical trials in advanced colorectal cancer ‘SPECTAcolor'https://esmogastro.org/article/S2949-8198(25)00037-8/fulltextKorea, Japan, Europe, and the United States: Why are guidelines for gastric cancer different?https://link.springer.com/article/10.1007/s10120-025-01613-xOutpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoringhttps://ascopubs.org/doi/10.1200/OP-25-00062Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancieshttps://ascopubs.org/doi/10.1200/PO-24-00896?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Study compared the prognostic impact of differing high-risk inclusion criteria used in the monarchE and NATALEE trials among patients with hormone receptor-positive/HER2-negative early #BreastCancer , using data from the MIG1, GIM2, and GIM3 trials. Patients were stratified into high- and low-risk cohorts per each trial's criteria, and further grouped into concordant low-risk, discordant risk, and concordant high-risk categories.Link to Articlehttps://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaf031/8002826?login=false#google_vignette

Oncology here & nowIn this interview Dr. Biagio Ricciuti of Dana Farber Cancer Institute (USA) talks to Dr. Marcelo Corassa of beneficência Portuguesa de São Paulo (Brazil) as they discuss Treatments in EGFR mutant Non Small Cell Lung Cancer. The discussion centers around the results of FLAURA, MARIPOSA and FLAURA2, future directions and much more.Join Us

Dear Colleagues,Welcome to the OncoAlert Weekly Round up Covering the TOP News and Trials THIS WEEK in Oncology. This week:Prognostic implications of risk definitions from the monarchE and NATALEE trialhttps://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaf031/8002826?login=false#google_vignetteEvaluating the impact of histological vs. nuclear grading on CPS + EG Score for HR + /HER2-early breast cancerhttps://link.springer.com/article/10.1007/s10549-025-07685-8?utm_content=buffer1d9c4&utm_medium=social&utm_source=twitter.com&utm_campaign=bufferFDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancerhttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancerCirculating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trialhttps://www.nature.com/articles/s41591-025-03579-wAssessment of a Polygenic Risk Score in Screening for Prostate Cancer (BARCODE1) https://nejm.org/doi/full/10.1056/NEJMoa2407934Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancerhttps://www.nature.com/articles/s41467-025-58435-9Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysishttps://www.annalsofoncology.org/article/S0923-7534(25)00130-9/abstract

Dr. van der Wilk dives into the results of the SANO Trial in Oesophageal Cancer and recently published on the Lancet Oncology. The phase 3 trial investigated whether active surveillance could be a non-inferior alternative to standard surgery in individuals with oesophageal cancer who achieved a clinical complete response after neoadjuvant chemoradiotherapy. Conducted in 12 Dutch hospitals, the study randomized 309 participants to either active surveillance or standard oesophagectomy. After a median follow-up of 38 months, the 2-year overall survival for active surveillance (74%) was non-inferior to that of standard surgery (71%), with no significant differences in postoperative complications or mortality between groups. These results suggest active surveillance could be a viable option for patient counseling and shared decision-making, although extended follow-up is needed to assess long-term efficacy.

The phase 3 LITESPARK-005 trial evaluated patient-reported outcomes (PROs) for belzutifan, a HIF-2α inhibitor, versus everolimus in patients with advanced renal cell carcinoma previously treated with immune checkpoint and anti-angiogenic therapy. 

Oncology Here & NowIn this interview, OncoAlert faculty members Dr. Joseph McCollom from Parkview Health (USA) and Dr. Cristiane Bergerot from OncoClinicas (Brazil) explore supportive care and the future of telemedicine. Their discussion spans the evolution of telehealth—from its pivotal role during the pandemic to its current applications—and what lies ahead.Join us for this insightful conversation!

Dr. Misty Shields guides us through this great paper out on Cancer (ACS) on the TOP advances in Small Cell Lung Cancer. Small cell lung cancer (SCLC) remains a leading cause of cancer mortality, with its aggressive nature and frequent relapse leading to poor outcomes. In recent years, immunotherapy has provided some survival benefits, and in 2024, key breakthroughs have significantly improved patient outcomes. Notable advances include the use of consolidative durvalumab immunotherapy for limited-stage SCLC, new insights into timing immunotherapy with radiation, and promising treatments such as the bispecific T-cell engager tarlatamab and antibody-drug conjugates. Precision medicine approaches, like neuroendocrine subtyping, may guide future treatments, while advocacy efforts, such as the Small Cell SMASHERS group @SCLCSMASHERS , offer new support for patients with this historically stigmatized disease.​Misty Dawn Shields MD PhD (Presenter and first author) Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA

Oncology Here & NowIn this interview, Dr. Elisa Agostinetto from the Jules Bordet Institute in Belgium speaks with Dr. Maryam Lustberg from Yale Cancer Center. Together, they dive deep into the use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer. Their discussion covers the use of Abemaciclib and Ribociclib following the monarchE and NATALEE trials, applications in the treatment of male breast cancer, and much more.Join us!

In this interview with Dr. Silke Gillessen & Dr. Aurelius Omlin , we delve into the origins, Topics and evolution of the Advanced #ProstateCancer Consensus Conference@APCCC_Lugano  began in 2015 to address critical questions in prostate cancer management where evidence is lacking or conflicting. Over the years, the conference has focused on various evolving topics, such as oligometastatic disease, treatment sequencing, and new imaging technologies. The 2024 APCCC highlighted major discussions on next-generation imaging, genomic biomarkers, and diagnostic challenges, with a strong emphasis on the need to balance cutting-edge technology with clinical practicality. Looking ahead to APCCC 2026, the event will continue to address key issues, including the risk of overtreatment, international disparities in imaging access, and the integration of comorbidities into treatment decision-making. With a welcoming atmosphere, APCCC invites healthcare professionals worldwide to engage in these important discussions and contribute to shaping the future of prostate cancer care.

Welcome to this OncoAlert Session Round Up during ASH24, focusing on Multiple Myeloma pharmacologic therapies.GMMG-HD7 Trial (JCO Publication)This phase 3 trial evaluated adding isatuximab (Isa) to the standard RVd (lenalidomide, bortezomib, dexamethasone) regimen in transplant-eligible patients with newly diagnosed multiple myeloma. Part 1 randomized 662 patients to Isa-RVd or RVd, followed by autologous stem cell transplantation and a second randomization to lenalidomide or Isa-lenalidomide maintenance. Isa-RVd showed higher minimal residual disease (MRD) negativity rates post-transplant (66% vs 48%) and improved progression-free survival (PFS) with a hazard ratio of 0.70 (P = .0184). Isa-RVd plus lenalidomide maintenance further improved PFS (P = .016), underscoring Isa's role in prolonging MRD negativity and PFS.IMROZ Trial (Phase 3)This trial analyzed Isa-VRd (isatuximab, bortezomib, lenalidomide, dexamethasone) versus VRd in transplant-ineligible patients with newly diagnosed multiple myeloma. Isa-VRd led to significant improvements in PFS and deeper, sustained MRD negativity, with 68.6% achieving MRD negativity by month 36 compared to 50.8% in the VRd group. Isa-VRd also resulted in lower MRD loss rates during maintenance and improved conversion from MRD positivity to negativity, leading to longer PFS. These findings highlight Isa-VRd's potential for faster, durable responses and support its use to improve long-term outcomes in these patients.UK MRA Myeloma XI+ TrialThe phase 3 UKMRA/NCRI Myeloma XI+ trial compared KRdc (carfilzomib, lenalidomide, dexamethasone, cyclophosphamide) to sequential triplet therapies (CRd, CTd) in newly diagnosed multiple myeloma patients. After a median follow-up of 102 months, KRdc improved PFS (56 vs 37 months, hazard ratio 0.69, P < 0.001) across cytogenetic risk groups, with higher MRD negativity rates. Early MRD negativity correlated with better PFS. While overall survival was similar in contemporaneously randomized patients (76% vs 71% at 60 months), non-contemporaneous controls showed an overall survival benefit with KRdc (76% vs 68%, hazard ratio 0.80, P = 0.011). These results emphasize the depth of responses with KRdc, particularly for high-risk patients, and the importance of early MRD negativity for improved PFS and survival.DREAMM-7 Trial (Phase 3)This trial compared belantamab mafodotin (BVd) versus daratumumab (DVd), both combined with bortezomib and dexamethasone, in relapsed/refractory multiple myeloma. BVd demonstrated a significant PFS benefit (36.6 vs 13.4 months, hazard ratio 0.41, P < 0.00001), with higher complete response and MRD negativity rates (25% vs 10%). BVd also showed a longer response duration (35.6 vs 17.8 months) and early trends favoring overall survival (84% vs 73% at 18 months). Median overall survival was not reached, but projections estimate 84 months for BVd versus 51 months for DVd. BVd's safety profile included manageable ocular events, positioning it as a promising option for relapsed/refractory multiple myeloma after first relapse.AQUILA Trial (NEJM Publication)This phase 3 trial evaluated subcutaneous daratumumab as monotherapy versus active monitoring in high-risk smoldering multiple myeloma. Among 390 patients, daratumumab reduced the risk of progression or death by 51% compared to monitoring (hazard ratio 0.49, P < 0.001) after a median follow-up of 65.2 months. At five years, PFS was 63.1% in the daratumumab group versus 40.8% in the monitoring group. Overall survival was higher with daratumumab (93.0% vs 86.9%). Daratumumab was well-tolerated, with hypertension being the most common grade 3 or 4 adverse event (5.7%), and no new safety concerns emerged. Daratumumab significantly delayed progression to active multiple myeloma and improved survival in high-risk patients.Disclosure: Supported by Sanofi.

In newly diagnosed multiple myeloma (NDMM), recent studies highlight the critical role of minimal residual disease (MRD) in guiding treatment decisions and improving outcomes. A significant trial showed that adding isatuximab (Isa) to lenalidomide, bortezomib, and dexamethasone (RVd) increased MRD negativity rates after induction therapy compared to RVd alone. MRD negativity was achieved in 50% of patients receiving Isa-RVd versus 36% in those receiving RVd. Additionally, Isa-RVd provided longer progression-free survival (PFS) in MRD-positive patients, though PFS was similar between Isa-RVd and RVd in MRD-negative patients. This suggests Isa offers a significant advantage for MRD-positive patients.After a median follow-up of 48 months, patients achieving MRD negativity after induction or transplant had significantly better PFS compared to those who remained MRD-positive. The GMMG-HD7 trial, the first phase 3 study to confirm the long-term benefits of achieving MRD negativity with an 18-week induction regimen, demonstrated that deep MRD responses can result in lasting benefits, even without post-transplant consolidation therapy. Future analyses will assess the role of maintenance therapy with or without isatuximab.Another study examined MRD progression (MRD-P) in NDMM patients treated with quadruplet therapy and autologous stem cell transplantation (ASCT). Though rare, MRD-P predicted imminent progression to full disease. Patients with MRD-P had shorter time to progression and poor survival free from failure of second-line therapy. MRD-P was driven by a plasma cell population resistant to existing therapies, including monoclonal antibodies, highlighting the need for new markers and treatment strategies for high-risk patients.The CEPHEUS phase 3 trial evaluated the addition of daratumumab (DARA) to the standard VRd regimen in NDMM patients who were transplant-ineligible or deferred transplant. The D-VRd combination significantly increased MRD negativity rates at both the 10^-5 and 10^-6 sensitivity thresholds and led to sustained MRD negativity in more patients than VRd alone. This deeper response resulted in superior PFS, with over 80% of MRD-negative patients remaining progression-free at 54 months. D-VRd improved outcomes in both MRD-positive and MRD-negative patients, positioning it as a new standard of care for transplant-ineligible or deferred patients.A final study explored whether sustained MRD negativity could allow for discontinuation of lenalidomide maintenance after ASCT. Patients who achieved sustained MRD negativity after three years of lenalidomide maintenance discontinued therapy, with MRD testing every six months. Of the 194 patients, 26.3% achieved sustained MRD negativity, with most remaining MRD-negative for up to 30 months post-therapy. Only 23% became MRD-positive, and a small number progressed to active disease. Among those who restarted lenalidomide, the median time to progression was 9.5 months. This suggests sustained MRD negativity may serve as a marker for safely discontinuing lenalidomide, though further trials are needed to confirm these findings.In conclusion, MRD status plays a vital role in optimizing treatment and improving outcomes in NDMM. From the benefits of isatuximab and daratumumab in enhancing MRD negativity to the possibility of safely discontinuing maintenance therapy, MRD testing is proving essential in multiple myeloma management.Disclosure: Supported by Sanofi.

A great Pleasure to Present the first Advanced Prostate Cancer Consensus Conference #APCCC24 Webinar/Podcast on Management of patients with Advanced #ProstateCancer : Cases from #APCCC24LINK TO ARTICLEhttps://sciencedirect.com/science/article/pii/S0302283824026101

The  @OncoAlert Round Up Covering July 26-Aug 1, 2024   REGISTER at http://Oncoalert360.com or https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration DiscussingShield Blood test FDAApproved for #ColorectalCancer Screeninghttps://ascopost.com/news/july-2024/guardant-health-s-shield-blood-test-approved-by-the-fda-as-a-primary-screening-option-for-colorectal-cancer/INSIGHT Trial in #NSCLC https://thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00270-5/abstractCombining PSMA-PETand PROMISE in #ProstateCancer https://sciencedirect.com/science/article/pii/S1470204524003267Review in RCC #KidneyCancer @b_szabados @drfrankiejs @tompowles1 https://thelancet.com/journals/lancet/article/PIIS0140-6736(24)00917-6/abstract Immune & Gene Expressionin ER Low & Neg #BreastCancer by @vitti10 https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djae178/7724836?searchresult=1&login=false Top Advances of the year: #Immunotherapy & #EndometrialCancer @BanerjeeSusana @PelegHasson https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35417ASCOGuidelines on cannabis in Adults Cancerhttps://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35461?af=R

Welcome to this Hematology Round Up from #EHA24WE have focused on on Hematologic malignancies with abstracts presented on June 15nd, 2024The first presentation was abstract s100 This Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ) . Presented by Dr. FaconThis trial presentation had a concomitant publication on the @NEJMat #ASCO24 last weekhttps://lnkd.in/d2dRh6HpThe Second presentation was abstract S101THE LANDSCAPE OF TP53 MUTATIONS AND THEIR PROGNOSTIC IMPACT IN CHRONIC LYMPHOCYTIC LEUKEMIAhttps://lnkd.in/dYg6DqPTThe Next presentation was abstract S102FIRST RESULTS OF THE APOLLO TRIAL: A RANDOMIZED PHASE III STUDY TO COMPARE ATO COMBINED WITH ATRA VERSUS STANDARD AIDA REGIMEN FOR PATIENTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE PROMYELOCYTIC LEUKEMIAhttps://lnkd.in/d2ZM6Z4QThe Next presentation is abstract S103ASCIMINIB (ASC) PROVIDES SUPERIOR EFFICACY AND EXCELLENT SAFETY AND TOLERABILITY VS TYROSINE KINASE INHIBITORS (TKI) IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) IN THE PIVOTAL ASC4FIRST STUDYhttps://lnkd.in/dxiets8mOur final Presentation is Late breaking abstract 3438GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (GLOFIT-GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS OF A GLOBAL RANDOMIZED PHASE III TRIAL (STARGLO)https://lnkd.in/dMWxnyF4Thank you for your attention and enjoy #EHA24Disclosure: This Hematology Round Up was supported by Sanofi

Dear Colleagues,Welcome to this Hematology Round Up from hashtag#ASCO24 . WE have focused on Hematologic malignancies with 3 presentations which were presented on June 2nd, 2024The first presentation was the Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ) . Presented by Dr. FaconThis trial presentation came with a concomitant publication on the New England Journal of Medicine (NEJM).https://lnkd.in/d2dRh6HpThe Second Presentation was the Phase 3 randomized BENEFIT study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI). Presented by Dr. LeleuThis trial presentation came with a concomitant publication on Nature Medicinehttps://lnkd.in/dSjVvk7XThe final presentation was Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial. Presented by Dr Rodriguez-OteroDr. Landgren discussed how quadruple therapies showed higher rates of minimal residual disease (MRD) and longer progression-free survival compared to triplets, regardless of age and transplant eligibility, potentially making them a new standard of care for newly diagnosed Multiple Myeloma.He emphasized the importance of minimal residual disease as an endpoint in newly diagnosed multiple myeloma, suggesting that having it as an early endpoint for accelerated approval could give patients faster access to new therapies. However, he also highlighted that bortezomib increases the rate of peripheral neuropathy.Dr. Landgren pointed out that CD38 monoclonal antibodies narrow the gap between transplant-eligible, younger, and fit patients, and transplant-ineligible, older, and less fit patients with multiple myeloma.Thank you for your attention and enjoy ASCODisclosure: This Hematology Round Up was supported by Sanofi

✅ TheLancet Commission on #ProstateCancer ✅DESTINY-PanTumor01✅Osimertinib+Local tx for brain

The OncoAlert Weekly Round Up

What happens when Five Friends initially brought together by oncology meet up in Lugano for #APCCC24..........Magic...thats what!Join Renu, Declan, Brian, Tom and Gil on this insanely casual and fun conversation on the side 

The OncoAlert  Weekly Round UpCovering April 19-25, 2024REGISTER AT http://OncoAlert360.com OR https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registrationDiscussingADCs in #LungCancer & #BreastCancer Out on @Annals_Oncologyhttps://annalsofoncology.org/article/S0923-7534(24)00108-X/abstractTILS in #TNBChttps://jamanetwork.com/journals/jama/article-abstract/2816923TROPION in #BreastCancerhttps://ascopubs.org/doi/full/10.1200/JCO.23.01909DE-REAL in #BreastCancer https://academic.oup.com/oncolo/article/29/4/303/7444338?login=falseCheckMate9ER in #kidneycancerhttps://esmoopen.com/article/S2059-7029(24)00762-2/fulltext#%20INNOVATED out on @ESMO_Open POP RT in #ProstateCancer https://redjournal.org/article/S0360-3016(24)00439-5/abstract#%20Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trialhttps://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35333

✅Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma out on @NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2312695#ap0✅Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial https://www.annalsofoncology.org/article/S0923-7534(24)00105-4/fulltext✅Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrumhttps://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(24)00185-X✅Three-year overall survival outcomes and correlative analyses in patients with non–small-cell lung cancer and high (50-89%) versus very high (≥90%) PD-L1 expression treated with first-line pembrolizumab or cemiplimabhttps://www.jtocrr.org/article/S2666-3643(24)00045-6/fulltext✅The Lancet Breast Cancer Commissionhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00747-5/fulltext✅Top advances of the year: Uterine cancerhttps://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.35321

The  @OncoAlert RoundUp is OutCovering April 5th-12th, 2024REGISTER at http://OncoAlert360.com OR https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration Discussing: @US_FDA  approval trastuzumab dxDurvalumab in Small Cell #LungCancer ALINA  #NSCLC out on @NEJM CD70 CART in #KidneyCancerAdagrasib Cetux in #colorectalcancer and more

The Top News, publications and trials in Oncology for the week of March 28- April 4, 2024SENOMAC out in NEJM on Breast CancerACS & IARC 2022 Cancer Statisticsand more

JAVELIN Renal 101 Out on Cancer DiscoveryFASTRACK II Out on Lancet OncologyONE SHOT (in Prostate cancer) Out on the Green Journal

Contact 02Embark/GETUG 18FORMULA 509BRCA Away

Discussing:Updated Cancer statistics from American Cancer SocietyNORPACT 1 in #PancreaticCancer  FDA approval in Cervical CancerImmune onc advances in GU Onc from the ASCO Ed bookLow dose SOC Olanzapine in NauseaGenomic Landscape of acquired resistance to PDL1 in #NSCLC and More

Discussing:  @ASCO @SocSurgOnc Germline Testing @ASTRO_org Partial Breast Irradiation in early Invasive Breast Cancer or DCIS ERMES in #ColorectalCancerVision in #ProstateCancerAMPLIFY 201 #Cance #vaccine in CRCNACI study in #CervicalCancer FUTURE-SUPER trial in #TNBC Adj Abemaciclib+ET in HR+HER- HighRisk 

Discussing:KeyNote A39 in #BladderCancerCheckMate 77Tin #LungCancerTropion Breast01 in #BreastCancerPooled CtDNA analysis of MONALEESAModulation Microbiota toenhance #Immunotherapy  and more.....

The @OncoAlert Newsletter  September 21, 2023Register at http://OncoAlert360.comDiscussing:VP-2023 HRQoL in NATALEE #BreastCancerOligomets in #ProstateCancer  treated w SBRTEV301: Enfortumab VendotinChemo in Urothelial CaTargeting Innate immune pathways in Cancer #ImmunotherapyOsimertinib early dose reduction as risk to brain mets in EGFR mutant #NSCLC #LungCancer

SPECIAL  LUNG CANCER PODCAST #WCLC23 World Conference #LungCancer TO GET IT REGISTER AT: http://OncoAlert360.comFLAURAMARSTMN StagingDESTINY LUNGHerthenaTRIDENTEVOKEISABRRIOTand moreA great way to catch up on all the great Science presented in Singapore

The  @oncoAlert  Round UpSeptember 1- 7, 2023 REGISTER TO GET IT at  http://OncoAlert360.com Discussing: @fda Breakthrough therapy designations for Trastuzumab deruxtecanSequencing Endocrine & Targeted Txin Hormone sensitive HER2- #breastcancerNeoadj palbociclib+giredestrant or anastrozole in ER+, HER2- early breast #cancerExercise& Nutritionon Chemo Completion & pCR in Breast #CancerBladder-Sparing Treatment w/ Radical Dose RT Is Effective Alternative to Radical Cystectomy in Node+ Nonmets and more...

Discussing:EMAapproval of Pembro+Trastuzumab+Chemo in Gastric Cancer based on KeyNote 811LUNARin metastatic #NSCLC ASTRRAin #BreastCancerCannabinioidsin children with #Cancer IO in treatment of Localised GU CancersLMWH synergistically enhances efficacy of adoptive and anti-PD-1-based #Immunotherapy .....and moreRegister at www.oncoalert360.com

LITESPARK005 in #KidneyCancerTBCRC 030 in TN #BreastCancerCONTACT02in #prostatecancerMRIto help diagnose #ProstateCancerLIBRETTO 531in #ThyroidCancerSBRT in HCC #LiverCancer

Case DiscussionLocalised High Risk #ProstateCancer 58yr old maleDRE: Hard mass c3PSA 12.4Gleasons 4+5=9Imaging M0later PSMA M1 in boneFaculty Dr. Neeraj AgarwalDr. Eleni EfstathiouDr. Axel MerseburgerDr. Sean McBride

Dear Colleagues,Welcome to the ASCO22 RoundUp for Day one of the congressStarting with with KRYstal1 with a concomitant publication in the New EnglandPhase One report of Adagrasib in Non Small Cell Lung Cancer, targeting KRAS G12C shows promise in  clinical efficacy without new safety signalsLarge number of response median follow-up of 12.5 monthsthe median PFS 6.5 months  median OS 12.6 monthsThe EVEREST TrialAdjuvant everolimus improves RFS in resected renal cell carcinoma in over 1,500 patients6-year estimated RFS was 64% for everolimus Vs 61% placebo.Just missing respecified 0.0222 significance. That is a minimal improved RFS with significantly higher AEs.There was a 21% improvement in RFS in everolimus in those with high risk for recurrence with no benefit seen in those in an intermediate high-risk group.Update of COSMIC-021 TrialThis was first-line treatment in urothelial carcinoma Combining Cabo/Atezo shows encouraging results with manageable toxin patients who were ineligible for cisplatincisplatin eligible or with 1 prior immune checkpoint inhibitor and no prior VEGF TKIsOR 20% in cisplatin-ineligible patients,30% in cisplatin-eligible patients,10%for those w prior ICI.Lung-MAP S1800Ain Second-line pembrolizumab plus ramucirumab in Non Small Cell Lung CancerHere there was a possible survival benefit with immune checkpoint inhibitor resistance VS Standard of care This is the first successful trial in the second-line setting for advanced NSCLC in those withAcquired resistance to immune checkpoint inhibitor therapy with out a Chemo backboneGreat to see lung cancer patients who progressed on prior immunotherapy, living significantly longer when treated with the combo of Pembrolizumab plus ramucirumab OS 14.5 months vs 11.6 monthsVery encouragingCheckmate 9ERDepth of response to  nivolumab plus cabozantinib is associated with durable efficacy and improved prognosis in previously untreated advanced renal cell carcinomaThe 12-month PFS rate for patients with the deepest responses in nivo cabo was 46.2% Vs 27.4% in sunitinib.The 18-month OS rate was twice as high in nivolumab plus cabozantinib 37.9% vs 17.4%)An improvement in Prognosis!And those are just SOME of the top trials presented at DAY1 of ASCO22 Looking forward to an Amazing Day 2Reminding everyone to mask up and enjoy ASCO

41 year female, no past medical history Comes to MedOnc after left breast lumpectomy & SN evaluationPath: 2.1 cm grade 2 tumor ER 100%PR 90%Her2 1+ FISH-1/2 Sentinel Node positive (4mm tumor deposit w/extranodal extension)Systemic staging-OncotypeDX 20#BreastCancer #OncoAlertTBDr. HamiltonDr. LustbergMs. MapesDr. LambertiniDr. Meattini ModeratorsDr. Grainne O'kaneDr. Ben WestphalenHostDr. Gil Morgan

The case42 year old female never smoker Comes to the ER with sudden onset chest painRadiology finds 4.2cm left-sided lung mass & enlarged mediastinal LN on staging PET/CT and Brain MRI. Staged as cT2bN2 (Stage IIIA) #NSCLCSurgically resectable#lungcancer #LCSM #OncoAlertTB ExpertsDr. Narushka NaidooDr. Jack WestDr. Brendon StilesDr. Henning WillersDr. Christian RolfoModeratorsDr. Grainne O'kaneDr. Ben WestphalenHostDr. Gil Morgan

First data from CODEBREAKSotorasib in G12C mutant Pancreatic Cancer Presented Feb 15, 2022 by Dr. John Strickler of Duke Medical Center